ORIGINAL RESEARCH PAPER
Volume - 15 | Issue - 02 | February - 2026 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

FORMULATION DEVELOPMENT AND EVALUATION OF OLANZAPINE SYRUP: A REVIEW

Pharmacology

Mr. Himanshu Singh
Dr. Abhay Pratap Singh
Dr. Jai Narayan Mishra
Dr. Dhaneshwar Kumar Vishwakarma

ABSTRACT

Schizophrenia is a chronic and debilitating psychiatric disorder requiring long-term pharmacological management, where patient adherence is critical for therapeutic success[1]. Olanzapine, a second-generation antipsychotic, is widely prescribed for schizophrenia, bipolar disorder, and treatment-resistant depression due to its broad receptor antagonism and proven clinical efficacy[2]. However, conventional solid dosage forms of olanzapine are associated with limitations such as swallowing difficulties, poor dose flexibility, and reduced adherence, particularly in pediatric, geriatric, and dysphagic populations[3-5]. Liquid dosage forms, especially syrups, offer a patient-friendly alternative by improving ease of administration, palatability, and dose titration[6]. The formulation of olanzapine syrup presents significant challenges owing to poor aqueous solubility, chemical instability, and bitter taste[7,8]. This review critically discusses the pharmacological and physicochemical properties of olanzapine, the rationale for syrup formulation, formulation strategies, excipient selection, application of Quality by Design (QbD) principles, and evaluation parameters. Recent advances in olanzapine formulation research are also summarized, highlighting the relevance of syrup formulations in improving patient compliance and therapeutic outcomes.

KEYWORDS

Olanzapine; Schizophrenia; Syrup Formulation; Liquid Dosage Form

INTRODUCTION

Schizophrenia is a severe and chronic psychiatric illness characterized by disturbances in perception, cognition, emotional regulation, and social behavior. It affects approximately 1% of the global population and represents a major public health burden[1]. Long-term antipsychotic therapy remains the cornerstone of schizophrenia management, with second-generation antipsychotics preferred due to their improved efficacy against negative symptoms and lower incidence of extrapyramidal side effects[2].

Olanzapine is one of the most extensively prescribed atypical antipsychotics and demonstrates significant efficacy in schizophrenia, bipolar disorder, and adjunctive treatment of depression[2]. Despite its effectiveness, medication non-adherence is frequently reported, with difficulty in swallowing solid dosage forms being a major contributing factor[4,5]. These limitations necessitate the development of alternative dosage forms that can enhance patient acceptability and adherence.

2. Pharmacological Profile of Olanzapine

Olanzapine is a thienobenzodiazepine derivative that exerts its therapeutic action through antagonism of multiple neurotransmitter receptors, including dopamine D_2, serotonin 5-HT_2A, muscarinic, histaminic H_1, and adrenergic α_1 receptors[3]. This multi-receptor binding profile contributes to its effectiveness against both positive and negative symptoms of schizophrenia. Clinically, olanzapine is administered in oral doses ranging from 5–20 mg per day, depending on disease severity and patient response[2].

Although olanzapine offers a favorable efficacy profile, it is associated with adverse effects such as weight gain, sedation, and metabolic disturbances, highlighting the importance of individualized dosing and careful titration[2]. Liquid dosage forms can facilitate precise dose adjustment during therapy initiation and maintenance.

3. Rationale for Liquid Dosage Forms

Commercially available olanzapine formulations include conventional tablets, orally disintegrating tablets, and intramuscular injections. However, these dosage forms present limitations in pediatric and geriatric patients, individuals with dysphagia, and patients experiencing acute psychotic episodes[3-5]. Studies indicate that approximately 26% of patients with schizophrenia exhibit medication non-adherence, with swallowing difficulty being a significant factor[5].

Liquid dosage forms such as syrups provide ease of administration, accurate dose flexibility, and improved palatability, making them suitable for individualized therapy and long-term use[6]. These attributes are particularly advantageous during dose titration and in patients unable to tolerate solid oral dosage forms.

4. Physicochemical Challenges in Olanzapine Syrup Formulation

Olanzapine is classified as a Bio pharmaceutics Classification System (BCS) Class II drug, characterized by low aqueous solubility and high permeability[7]. Its poor solubility in water can result in formulation instability, inconsistent drug content, and variable bioavailability. Additionally, olanzapine is susceptible to degradation under conditions of light, heat, and oxidative stress, which can compromise the stability of liquid formulations[9].

These challenges necessitate the incorporation of suitable solubilizing agents, pH modifiers, and protective excipients to ensure chemical and physical stability throughout the product's shelf life.

MATERIALS AND METHODS

The successful development of olanzapine syrup requires careful selection of excipients to enhance solubility, stability, and palatability. Solubilizing agents such as propylene glycol, polyethylene glycol, and glycerin are commonly employed[6]. Preservatives are incorporated to prevent microbial growth, while buffering agents maintain optimal pH conditions for drug stability. Sweetening and flavoring agents play a crucial role in masking the bitter taste of olanzapine and improving patient acceptability[9].

Method of Preparation

Olanzapine syrup is generally prepared by dissolving the drug in a suitable solubilizing system followed by incorporation into an aqueous vehicle containing sweeteners, preservatives, and flavoring agents. The formulation is optimized to achieve uniform drug distribution, acceptable viscosity, and microbiological stability.

Evaluation Parameters

The developed olanzapine syrup is evaluated for physicochemical parameters including appearance, pH, viscosity, density, refractive index, and drug content uniformity. Organoleptic properties such as taste, color, and odor are assessed to ensure patient acceptability[6].

Microbiological evaluation, including preservative efficacy testing and microbial limit tests, is essential to confirm product safety. Stability studies conducted according to ICH guidelines provide critical information on shelf life and appropriate storage conditions[8].

RESULTS AND DISCUSSION

Literature evidence suggests that optimization of solubilizing systems and excipient composition can significantly enhance the solubility and stability of olanzapine in liquid dosage forms[6,7]. Application of Quality by Design (QbD) principles enables identification of critical quality attributes and formulation variables, ensuring consistent product performance[10].

Comparative studies indicate that liquid formulations offer superior dose flexibility and improved patient compliance compared to solid dosage forms, particularly in populations with swallowing difficulties[5]. Stability studies on liquid olanzapine preparations have demonstrated acceptable chemical and microbiological stability when stored under appropriate conditions.

Quality by Design (QbD) in Olanzapine Syrup Development-

Quality by Design is a systematic, science-based approach that emphasizes understanding formulation and process variables to ensure consistent product quality[10]. In olanzapine syrup development, QbD involves defining the quality target product profile, identifying critical quality attributes such as drug content, pH, viscosity, and stability, and establishing a design space to minimize variability. This approach enhances formulation robustness and regulatory acceptability.

CONCLUSION

The development of an olanzapine syrup represents a clinically and pharmaceutically valuable strategy to overcome limitations associated with conventional solid dosage forms. Liquid formulations improve ease of administration, enable precise dose titration, and enhance patient adherence, particularly in vulnerable populations. Although challenges related to poor solubility and stability exist, these can be effectively addressed through appropriate excipient selection, application of QbD principles, and comprehensive evaluation. A standardized olanzapine syrup has the potential to fulfill an unmet clinical need and improve therapeutic outcomes in the management of schizophrenia and related psychiatric disorders.

REFERENCES

1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
2. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10(5):280–291.
3. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96.
4. Liu F, Ranmal S, Batchelor HK, Orlu-Gul M, Ernest TB, Thomas IW, et al. Patient-centered pharmaceutical design to improve acceptability of medicines in paediatric and geriatric populations. Drugs. 2014;74(16):1871–1889.
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia. J Clin Psychiatry. 2002;63(10):892–909.
6. Allen LV, Popovich NG, Ansel HC. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
7. Thombre AG, Cardinal JR, DeNoto AR, Herbig SM, Smith KL. Asymmetric membrane capsules for osmotic drug delivery. J Control Release. 1999;57(1):55–64.
8. Bakshi M, Singh S. Development of validated stability-indicating assay methods. J Pharm Biomed Anal. 2002;28(6):1011–1040.
9. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals. Drug Dev Ind Pharm. 2004;30(5):429–448.
10. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783.